Last reviewed · How we verify
Bromfenac Ophthalmic Solution B
Bromfenac Ophthalmic Solution B is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. Used for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.
At a glance
| Generic name | Bromfenac Ophthalmic Solution B |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, bromfenac decreases production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. The ophthalmic solution formulation allows direct delivery to the anterior segment.
Approved indications
- Postoperative inflammation and pain following cataract surgery
- Ocular itching associated with allergic conjunctivitis
Common side effects
- Ocular irritation
- Stinging or burning upon instillation
- Conjunctival hyperemia
- Headache
Key clinical trials
- Control of Pain in Intravitreal Injections Using Topical NSAIDs (PHASE4)
- A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromfenac Ophthalmic Solution B CI brief — competitive landscape report
- Bromfenac Ophthalmic Solution B updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about Bromfenac Ophthalmic Solution B
What is Bromfenac Ophthalmic Solution B?
How does Bromfenac Ophthalmic Solution B work?
What is Bromfenac Ophthalmic Solution B used for?
Who makes Bromfenac Ophthalmic Solution B?
What drug class is Bromfenac Ophthalmic Solution B in?
What development phase is Bromfenac Ophthalmic Solution B in?
What are the side effects of Bromfenac Ophthalmic Solution B?
What does Bromfenac Ophthalmic Solution B target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting Cyclooxygenase (COX-1 and COX-2)
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Postoperative inflammation and pain following cataract surgery
- Indication: Drugs for Ocular itching associated with allergic conjunctivitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing